RecruitingNCT07597122

MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

56 participants

Start Date

Jun 1, 2026

Study Type

OBSERVATIONAL

Conditions

Sepsis and septic shock

Summary

Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.

Eligibility

Min Age: 18 Years

Inclusion Criteria13

Septic shock:
New onset (<24h) of septic shock diagnosis according to Sepsis-3 definition
(suspected) infection
Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)
Serum lactate level > 2mmol/L
Minimum age of 18 years
Expected length of stay >48h
Written consent from an independent physician
Critically ill:
Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis/septic shock according to Sepsis-3 definition
Minimum age of 18 years
Expected length of stay >48h
Written consent from an independent physician

Exclusion Criteria5

Age < 18 years
Patients known not to speak German or French
Patients with known.
Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or
current immunosuppressive therapy (immunosuppressive biologicals or active lymphocyte therapy e.g. endoxan, rituximab or corticosteroid use at a dose > 10 mg/day equivalent of prednisone. However, acute corticosteroid treatment of a relative adrenal insufficiency using a maximum hydrocortisone dose of 200 mg/day is accepted.

Interested in this trial?

Get notified about updates and connect with the research team.